A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Jonathan Welte
Advertisement
With Simon-Kucher & Partners’ life sciences division
Articles by Jonathan Welte
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Rebuilding Clinical Data Workflows for the AI Era
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5